InvestSMART

Chimeric Therapeutics Limited (ASX: CHM) - Announcements

- Current share price for CHM : $0.003

ASX company news and announcements for Chimeric Therapeutics Limited (CHM) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Chimeric Therapeutics Limited (CHM) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Chimeric Therapeutics Limited (CHM), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Chimeric Therapeutics Limited (CHM)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$0 Change of Director's Interest Notice - MP 19 Dec 2025 11:12AM $0.003 $0.003 fallen by 0%
$0 Trading Halt 19 Dec 2025 9:30AM $0.003 $0.003 fallen by 0%
$0 CDH17 granted FDA Orphan Drug Designation for Gastric Cancer 8 Dec 2025 8:33AM $0.003 $0.003 fallen by 0%
$0 Company update-board changes, shareholder feedback & support 28 Nov 2025 9:27AM $0.003 $0.003 fallen by 0%
$0 Final Director's Interest Notice - PH 26 Nov 2025 6:08PM $0.003 $0.003 fallen by 0%
$0 Results of Meeting 25 Nov 2025 1:02PM $0.003 $0.003 risen by 20%
$0 Presentation to AGM 25 Nov 2025 8:31AM $0.003 $0.003 fallen by 0%
$0 CHIMERIC RECEIVES $4.5M R&D TAX INCENTIVE 24 Nov 2025 10:00AM $0.003 $0.003 fallen by 0%
$0 75% disease control observed in CHM CDH17 trial 13 Nov 2025 10:22AM $0.003 $0.003 fallen by 0%
$0 CHM CORE NK Combination Phase 1b trial update 13 Nov 2025 10:21AM $0.003 $0.003 fallen by 0%
$0 Pause in Trading 13 Nov 2025 10:09AM $0.003 $0.003 fallen by 0%
$0 Response to ASX Query Letter 6 Nov 2025 10:47AM $0.003 $0.003 fallen by 0%
$0 Quarterly Activities/Appendix 4C Cash Flow Report 31 Oct 2025 4:58PM $0.003 $0.003 fallen by 0%
$0 Notice of Annual General Meeting/Proxy Form 27 Oct 2025 9:58AM $0.003 $0.003 fallen by 0%
$0 Becoming a substantial holder 10 Oct 2025 4:34PM $0.004 $0.003 fallen by 14.29%
$0 Notification regarding unquoted securities - CHM 10 Oct 2025 4:24PM $0.004 $0.003 fallen by 14.29%
$0 Application for quotation of securities - CHM 10 Oct 2025 4:12PM $0.004 $0.003 fallen by 14.29%
$0 Presentation to investor webinar 8 Oct 2025 9:15AM $0.004 $0.003 fallen by 25%
$0 Investor update webinar - 11am AEDT, Wednesday 8 Oct 3 Oct 2025 12:03PM $0.003 $0.003 fallen by 0%
$0 Additional complete responses in CHM CORE-NK Phase 1b trial 2 Oct 2025 9:42AM $0.003 $0.003 fallen by 0%
$0 Disease control and tumour shrinkage observed in CHM CDH17 29 Sep 2025 8:29AM $0.003 $0.003 fallen by 0%
$0 Presentation to investor webinar 9 Sep 2025 9:49AM $0.004 $0.003 fallen by 14.29%
$0 Corporate Governance Statement and Appendix 4G 29 Aug 2025 4:55PM $0.003 $0.003 fallen by 0%
$0 Appendix 4E and Annual Report 29 Aug 2025 4:55PM $0.003 $0.003 fallen by 0%
$0 Webinar - CHM CDH17 deep dive with Professor Jennifer Eads 26 Aug 2025 8:27AM $0.003 $0.003 fallen by 0%

76 - 100 of 650 results

Page 4 of 26

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.